EUVIMEDEUVIMED entdecken
Crossref

Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models

Shenshen Wu, Jun Yun, Weiyan Tang, Giuseppe Familiari iD, Michela Relucenti, Jiong Wu, Xiaobo Li, Hanqing Chen, Rui Chen iD

ACS Nano · 27.06.2023 · 17 (12) · 11838-11854

DOI: 10.1021/acsnano.3c03050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 13.06.2023. Verfasst von Shenshen Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Capital Medical University, Beijing 100069, China. Hauptthemen laut MEDLINE: Exosomes, Colorectal Neoplasms. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: NIEHS NIH HHS, National Institute of Environmental Health Sciences, Beijing Municipal Commission of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although therapeutic targets have been developed for colorectal cancer (CRC) therapy, the therapeutic effects are not ideal and the survival rate for CRC patients remains poor. Therefore, it is crucial to recognize a specific target and develop an efficacious delivery system for CRC therapy. Herein, we demonstrate that reduced ALKBH5 mediates aberrant m6A modification and tumor progression in CRC. Mechanically, histone deacetylase 2-mediated H3K27 deacetylation inhibits ALKBH5 transcription in CRC, whereas ectopic ALKBH5 expression decreases tumorigenesis of CRC cells and protects mice from colitis-associated tumor development. Further, METTL14/ALKBH5/IGF2BPs combine to modulate JMJD8 stability in an m6A-dependent manner, which increases glycolysis and accelerates the development of CRC by enhancing the enzymatic activity of PKM2. Moreover, ALKBH5 mRNA-loaded folic acid-modified exosome-liposome hybrid nanoparticles were synthesized and significantly inhibit the progression of CRC in preclinical tumor models by modulating the ALKBH5/JMJD8/PKM2 axis and inhibiting glycolysis. Overall, our research confirms the crucial function of ALKBH5 in regulating the m6A status in CRC and provides a direct preclinical approach for using ALKBH5 mRNA nanotherapeutics for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesColorectal NeoplasmsMiceAnimalsRNA, MessengerLiposomesCarcinogenesis

Stichwörter der Autor:innen

ALKBH5CRCRNA methylationexosome−liposome hybrid nanoparticlesmRNA therapeutics

Substanzen

RNA, MessengerLiposomes

Autor:innen und Institutionen

  • School of Public Health, Capital Medical University, Beijing 100069, China.
  • Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.
  • Medical Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China.
  • Department of Anatomical, Histological, Medical and Legal Locomotive Apparatus, Section of Human Anatomy Via Alfonso Borelli, Sapienza University of Rome, Roma 5000161, Italy.
  • Department of Anatomical, Histological, Forensic Medicine and Orthopedic Science, Sapienza University of Rome, Roma 5000161, Italy.
  • School of Life Sciences, Jiangsu Normal University, Xuzhou 221116, China.

ORCID-Profile: Giuseppe Familiari, Rui Chen

Förderung

  • NIEHS NIH HHS
  • National Institute of Environmental Health Sciences
  • Beijing Municipal Commission of Education
  • National Science Fund for Distinguished Young Scholars
  • National Natural Science Foundation of China
  • Youth Beijing Scholar Program

Zitieren

APA

Wu, S., Yun, J., Tang, W., Familiari, G., Relucenti, M., Wu, J., Li, X., Chen, H., & Chen, R. (2023). Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models. ACS Nano, 17(12), 11838-11854. https://doi.org/10.1021/acsnano.3c03050

Vancouver

Wu S, Yun J, Tang W, Familiari G, Relucenti M, Wu J, et al. Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models. ACS Nano. 2023;17(12):11838-11854. doi:10.1021/acsnano.3c03050

BibTeX
@article{Wu2023,
  author = {Wu, Shenshen and Yun, Jun and Tang, Weiyan and Familiari, Giuseppe and Relucenti, Michela and Wu, Jiong and Li, Xiaobo and Chen, Hanqing and Chen, Rui},
  title = {Therapeutic m 6 A Eraser ALKBH5 mRNA-Loaded Exosome–Liposome Hybrid Nanoparticles Inhibit Progression of Colorectal Cancer in Preclinical Tumor Models},
  journal = {ACS Nano},
  year = {2023},
  volume = {17},
  number = {12},
  pages = {11838--11854},
  doi = {10.1021/acsnano.3c03050}
}
Kostenlos starten →